Cannabidiolic acid outperformed riluzole as a neuroprotective treatment in an ALS mouse model
CBDA (the raw, unheated form of CBD) proved the most effective of five cannabinoids tested in an ALS mouse model, outperforming the standard ALS medication riluzole in preserving motor neurons and reducing neuroinflammation.
Quick Facts
What This Study Found
Among five phytocannabinoids tested, CBDA at 10 mg/kg was the most effective, improving motor coordination, reducing neuronal cell death and neuroinflammation, and shifting microglia from pro-inflammatory to anti-inflammatory. CBDA showed superior neuroprotection compared to riluzole on most measures.
Key Numbers
Optimal dose: 10 mg/kg CBDA. Five cannabinoids compared. Treatment period: day 65-90. Higher CBDA doses caused toxicity. CBD + riluzole combination did not enhance efficacy.
How They Did This
Preclinical study in Prp-hTDP-43(A315T) transgenic male mice, an ALS model, treated from early symptomatic (day 65) to advanced stages (day 90). Five cannabinoids compared, followed by CBDA dose-response testing and comparison with riluzole.
Why This Research Matters
ALS has extremely limited treatment options. If CBDA consistently outperforms riluzole in preclinical models, it could warrant clinical trials as either an alternative or adjunct therapy.
The Bigger Picture
CBDA is the acidic precursor to CBD found in raw cannabis. Its superior performance here suggests raw cannabinoid acids deserve more research attention, as they may have distinct therapeutic profiles.
What This Study Doesn't Tell Us
Only male mice were tested. The TDP-43 model represents one ALS subtype. Higher doses caused toxicity, suggesting a narrow therapeutic window.
Questions This Raises
- ?Why was the CBD-riluzole combination less effective than CBDA alone?
- ?Would CBDA show similar benefits in female mice or other ALS models?
Trust & Context
- Key Stat:
- optimal CBDA dose that improved motor function and preserved motor neurons in ALS mice, outperforming riluzole
- Evidence Grade:
- Rigorous preclinical design with dose-response testing, active comparator, and mechanistic characterization, though limited to male mice and one ALS model.
- Study Age:
- 2025 publication.
- Original Title:
- Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis.
- Published In:
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189, 118288 (2025)
- Authors:
- García-Toscano, Laura, Rodríguez-Cueto, Carmen, Furiano, Anna, Hind, William, de Lago, Eva, Fernández-Ruiz, Javier
- Database ID:
- RTHC-06508
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is CBDA?
CBDA (cannabidiolic acid) is the raw, unheated precursor to CBD found naturally in the cannabis plant. When cannabis is heated, CBDA converts to CBD. This study suggests CBDA may have distinct and potentially stronger neuroprotective properties.
Why did combining CBD and riluzole not work better?
The combination actually weakened the microglial response benefits, suggesting potential interference between the two compounds.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06508APA
García-Toscano, Laura; Rodríguez-Cueto, Carmen; Furiano, Anna; Hind, William; de Lago, Eva; Fernández-Ruiz, Javier. (2025). Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189, 118288. https://doi.org/10.1016/j.biopha.2025.118288
MLA
García-Toscano, Laura, et al. "Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis.." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. https://doi.org/10.1016/j.biopha.2025.118288
RethinkTHC
RethinkTHC Research Database. "Preclinical evaluation of cannabidiolic acid as a neuroprote..." RTHC-06508. Retrieved from https://rethinkthc.com/research/garcia-toscano-2025-preclinical-evaluation-of-cannabidiolic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.